Donald School Journal of Ultrasound in Obstetrics and Gynecology

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  18 (2024)
Volume  17 (2023)
Volume  16 (2022)
Volume  15 (2021)
Volume  14 (2020)
Volume  13 (2019)
Volume  12 (2018)
Volume  11 (2017)
Volume  10 (2016)
Volume  9 (2015)
Volume  8 (2014)
Volume  7 (2013)
Volume  6 (2012)
Volume  5 (2011)
Volume  4 (2010)
Volume  3 (2009)
Volume  2 (2008)
Volume  1 (2007)
Related articles

VOLUME 8 , ISSUE 1 ( January-March, 2014 ) > List of Articles

RESEARCH ARTICLE

Psychotropic Medication Use during Pregnancy and Lactation: Role of Ultrasound Assessment

Ritsuko Pooh, Andrew Matthys, Maria Teresa Ambat

Keywords : Psychotropic medication,Pregnancy,Birth defects,Teratogens,Ebstein's anomaly,Withdrawal,SSRIs,TCAs,Anticonvulsants,Valproate,Valproic acid,Carbamazepine,Lamotrigine,Antipsychotics,Haloperidol,Olanzapine,Benadryl,Lithium

Citation Information : Pooh R, Matthys A, Ambat MT. Psychotropic Medication Use during Pregnancy and Lactation: Role of Ultrasound Assessment. Donald School J Ultrasound Obstet Gynecol 2014; 8 (1):109-121.

DOI: 10.5005/jp-journals-10009-1345

License: CC BY-NC 4.0

Published Online: 01-12-2014

Copyright Statement:  Copyright © 2014; The Author(s).


Abstract

How to cite this article

Matthys A, Ambat MT, Pooh R, Kupesic Plavsic S. Psychotropic Medication Use during Pregnancy and Lactation: Role of Ultrasound Assessment. Donald School J Ultrasound Obstet Gynecol 2014;8(1):109-121.

PDF Share
  1. USCB. Available at: http://www.census.gov/population/international/(Retrieved on August 24, 2012)‥
  2. September 1, 1992 through March 31, 2001. Available at: http://pregnancyregistry.gsk.com/documents/lam_spring_2010_final_ report.pdf (Accessed on October 18, 2013)‥
  3. Drug usage in pregnancy. In: Lewis P, editor. Clinical pharmacology in obstetrics. Boston, Wright-PSG, 1983;p. 22-35.
  4. Embryotoxic drugs. Bio Res Pregnancy Perinatol 1985; 6:1-4.
  5. Problems of Lithium maintenance treatment during pregnancy, delivery and lactation. Agressolgie 1980; 21:714-716.
  6. Drugs in pregnancy and lactation. 2nd ed. Baltimore: Williams & Wilkins, 1986;p. 321-329.
  7. The use of lithium during pregnancy and lactation. J Clin Psychiatry 1983;44:358-365.
  8. When a woman taking lithium wants to have a baby. Massachusetts General Hospital Newsletter. Biol Ther Psychiatry 1983;6:19-24.
  9. Lithium treatment of women during pregnancy and the post-delivery period. In Johnson FN, editor. Handbook of Lithium Therapy. Lancaster, England: MTP Press 1980;p. 421-429.
  10. Lithium-related congenital cardiac abnormalities: Prenatal screening. Massachusetts General Hospital Newsletter Biol Ther Psychiatry 1983;6:7-12.
  11. Letter: Prenatal echocardiographic screening for Ebstein's anomaly for mothers on lithium therapy. Lancet 1982;2:875-878.
  12. Outcome after rapid discontinuation of lithium treatment in bipolar mood disorders. Arch Gen Psychiatry 1993; 50:448-453.
  13. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet 1992; 339:530-533.
  14. Letter: Lithium and placenta. Am J Obstet Gynecol 1975; 122:541-547.
  15. Nephrogenic diabetes insipidus in transplacental lithium intoxication. J Pediatr 1979; 94:493-502.
  16. Psychotropic medication in pregnancy. Advances in Psychiatric Treatment 2004;10:59-66.
  17. Pregnancy outcome following gestational exposure to venlaxafine: A multicenter prospective controlled study. Am J Psychiatry 2001;158:1728-1733.
  18. Association between cleft lip with or without cleft palate and prenatal exposure to diazepam. Lancet 1975;2:478-484.
  19. Lack of relation of oral clefts to diazepam use during pregnancy. N Engl J Med 1983; 309:1282-1285.
  20. Diazepam in labour: Its metabolism and effect on the clinical condition and thermogenesis of the newborn. BMJ 1973; 4:251-257.
  21. Withdrawal symptoms in the neonates from intrauterine exposure to diazepam. J Pediatr 1977; 90: 123-130.
  22. Side effects on fetus and infant of psychotropic drug use during pregnancy. Int Pharmacopsychiatry 1976; 11:246-252.
  23. Neonatal alprazolam withdrawalpossible effects of breast feeding. Drug Intell Clin Pharm 1989; 23:614-620.
  24. Letter: Abnormalities in children exposed to benzodiazepines in utero. Lancet 1987; 1:108-115.
  25. Maternal health and congenital defect. N Engl J Med 1958; 258:767-772.
  26. Pregnancy outcome following first trimester exposure to fluoxetine (Prozac). JAMA 1993; 269:2246-2252.
  27. Birth defects and drugs in pregnancy. Littleton, MA: PSG Publishing 1977;pp 345-347.
  28. Course of psychiatric disorders in pregnancy: dilemmas in pharmacological management. Neurol Clin 1994;12:6138.
  29. The fetal valproate syndrome. Am J Med Genet 1984 19:47380.
  30. Fetal valproate syndrome: Is there a recognizable phenotype? J Med Genet 1987;24:692-696.
  31. Fetal growth, major malformations and minor anomalies in infants born to women receiving valproic acid. J Pediatr 1986; 108:997-999.
  32. Prenatal exposure to valproic acid during pregnancy and limb deficiencies: a case control study. Am J Med Genet 2000;9:376-382.
  33. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants: a collaborative study of the European Network of Teratology Information Services (ENTIS). Reproductive Toxicology 1996; 10:285-290.
  34. Pharmacologic management of psychiatric illness during pregnancy: Dilemmas and guidelines. American Journal of Psychiatry 1996;153:592-606.
  35. Delivery outcome after the use of antidepressants in early pregnancy. European Journal of Clinical Pharmacology 1999; 55: 503-508.
  36. Management of major depression during pregnancy. American Journal of Psychiatry 2002;159: 1667-1673.
  37. Antidepressant use during lactation. Journal of Human Lactation 2001;17:256-261.
  38. Antidepressant treatment during breast-feeding. American Journal of Psychiatry 1996; 153:1132-1137.
  39. Benzodiazepine use in pregnancy and major malformations or oral cleft. Meta-analysis of cohort and casecontrolled studies. BMJ 1998;317:839-843.
  40. Intrauterine hemorrhage associated with prenatal valproate exposure. Am J Genet 1998;64(Suppl 4):A159.
  41. Effects of antimanic mood stabilizing drugs on fetuses, neonates and nursing infants. South Med J 2001;94:304-305.
  42. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998; 279:609.
  43. Exposure to nonsteroidal antiinflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ 2003;327:368.
  44. Risk of adverse birth outcome and miscarriage in pregnant users of nonsteroidal anti-inflammatory drugs: population based observational study and case-control study. BMJ 2001; 322:266-269.
  45. Maternal serum-alpha-fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy. Report of UK collaborative study on alpha-fetoprotein in relation to neural-tube defects. Lancet 1977; 1:1323-1330.
  46. Ultrasound screening for spina bifida: cranial and cerebellar signs. Lancet 1986;2:724.
  47. Amniotic fluid acetylcholinesterase measurement in the prenatal diagnosis of open neural tube defects. Second report of the collaborative acetylcholinesterase Study. Prenat Diagn 1989; 9:813.
  48. Fetal MRI in the evaluation of fetuses referred for sonographically suspected neural tube defects (NTDs): impact on diagnosis and management decision. Neuroradiology 2009; 51:761.
  49. Efficacy of prenatal ultrasonography in confirmed club foot. J Bone Joint Surg Br 2002;84:1015.
  50. The risk for congenital heart defects in offspring of individuals with congenital heart defects. Clin Genet 2001; 59:325.
  51. Report of the New England Regional Infant Cardiac Program by Donald C. Fyler, MD, Pediatrics, 1980;65(suppl):375-461. Pediatrics 1998; 102:258.
  52. Cyanosis of the newborn infant. Recognition and clinical evaluation. J Pediatr 1970;77:484.
  53. Lamotrigine treatment as monotherapy during pregnancy. J Neurol 248(Suppl 2):146, 2001.
  54. Epilepsy and Pregnancy: A Prospective Register in the United Kingdom. Post presented at the XVII World Congress of Neurology London, GBR, June, 2001.
  55. Ebstein's malformation: a clinical and laboratory study. Medicine (Baltimore) 1956;35:161.
  56. Left heart lesions in patients with Ebstein anomaly. Mayo Clin Proc 2005; 80:361.
  57. Electrode catheters and the diagnosis of Ebstein's anomaly of the tricuspid valve. Br Heart J 1966; 28:161.
  58. Ebstein's anomaly associated with cardiomyopathy and pulmonary hypertension. Circulation 1964; 30:578.
  59. Two-dimensional echocardiographic spectrum of Ebstein's anomaly: detailed anatomic assessment. J Am Coll Cardiol 1984; 3:356.
  60. Neurological examination: Normal and abnormal features. In: Neurology of the Newborn, 4th ed, WB Saunders, Philadelphia 2001. p. 103.
  61. Clinical practice. Depression during pregnancy. N Engl J Med 2011; 365:1605.
  62. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm283375.htm#data(Accessed on December 15, 2011)‥
  63. Therapeutic drug monitoring in pregnant and postpartum women: recommendations for SSRIs, lamotrigine, and lithium. J Clin Psychiatry 2010;71:649.
  64. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006;77:193.
  65. Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Arch Neurol 2011; 68:1275.
  66. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 2008;70:2152.
  67. Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract 2009;15:183.
  68. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004;161:608.
  69. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996;153:592.
  70. Antenatal exposure to meprobamate and chlordiazepoxide in relation to malformations, mental development, and childhood mortality. N Engl J Med 1975; 292:726-729.
  71. Pregnancy registries in epilepsy: a consensus statement on health outcomes. Neurology 2008; 71:1109-1113.
  72. Use of selective serotoninreuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007;356:26848.
  73. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007;356:2675-2679.
  74. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 2007;79:301-306.
  75. Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. BMJ 2010; 341:c6581.
  76. Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation (of carbamazepine). Epilepsia 1984; 25:7782.
  77. Benzodiazepine use in pregnancy and major malformations or oral cleft: metaanalysis of cohort and case-control studies. BMJ 1998; 317: 839-842.
  78. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol Drug Saf 2007;16:1203-1205.
  79. Drugs in pregnancy. N Engl J Med 1998; 338:1128-1131.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.